GlassScriptPhysician profile
Ajay Nair
NPI 1558347013
$9,157.12
in general payments reported to CMS, 2019-2025
42 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $837 · 2021: $1,563 · 2022: $1,692 · 2023: $1,605 · 2024: $1,345 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.52 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,075.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $937.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $888.44 | 2019-2025 | |
| Novo Nordisk INC | $800.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.03 | 2020-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $352.81 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbott Laboratories | $349.12 | 2021-2025 | Freestyle Libre 2 |
| Astellas Pharma US INC | $237.21 | 2019-2025 | Veozah |
| Lilly USA, LLC | $230.79 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $222.91 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $186.74 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $177.73 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.44 | 2022 | |
| Amarin Pharma, INC. | $155.63 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.